IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.

Rudà R, Bruno F, Ius T, Silvani A, Minniti G, Pace A, Lombardi G, Bertero L, Pizzolitto S, Pollo B, Conti Nibali M, Pellerino A, Migliore E, Skrap M, Bello L, Soffietti R.

Neuro Oncol 2022; 24: 809-820. doi: 10.1093/neuonc/noab239. PMID: 34651653

https://pubmed.ncbi.nlm.nih.gov/34651653/